

Carrie A Schinstock

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3963408/publications.pdf>

Version: 2024-02-01

37
papers

1,336
citations

567144

15
h-index

377752

34
g-index

38
all docs

38
docs citations

38
times ranked

1582
citing authors

#	ARTICLE	IF	CITATIONS
1	The Banff 2019 Kidney Meeting Report (I): Updates on and clarification of criteria for T cell and antibody-mediated rejection. American Journal of Transplantation, 2020, 20, 2318-2331.	2.6	437
2	Recommended Treatment for Antibody-mediated Rejection After Kidney Transplantation: The 2019 Expert Consensus From the Transplantation Society Working Group. Transplantation, 2020, 104, 911-922.	0.5	172
3	Urinalysis is more specific and urinary neutrophil gelatinase-associated lipocalin is more sensitive for early detection of acute kidney injury. Nephrology Dialysis Transplantation, 2013, 28, 1175-1185.	0.4	71
4	32 Doses of Bortezomib for Desensitization Is Not Well Tolerated and Is Associated With Only Modest Reductions in Anti-HLA Antibody. Transplantation, 2017, 101, 1222-1227.	0.5	67
5	Interpreting Anti-HLA Antibody Testing Data. Transplantation, 2016, 100, 1619-1628.	0.5	52
6	Discordance Between Iothalamate and Iohexol Urinary Clearances. American Journal of Kidney Diseases, 2016, 67, 49-55.	2.1	52
7	Kidney Transplant With Low Levels of DSA or Low Positive B-Flow Crossmatch. Transplantation, 2017, 101, 2429-2439.	0.5	49
8	Use of Eculizumab for Active Antibody-mediated Rejection That Occurs Early Post-kidney Transplantation: A Consecutive Series of 15 Cases. Transplantation, 2019, 103, 2397-2404.	0.5	49
9	Managing highly sensitized renal transplant candidates in the era of kidney paired donation and the new kidney allocation system: Is there still a role for desensitization?. Clinical Transplantation, 2019, 33, e13751.	0.8	48
10	Long-term outcomes of eculizumab-treated positive crossmatch recipients: Allograft survival, histologic findings, and natural history of the donor-specific antibodies. American Journal of Transplantation, 2019, 19, 1671-1683.	2.6	48
11	KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors. American Journal of Kidney Diseases, 2020, 75, 299-316.	2.1	38
12	De novo donor-specific antibody following <sc>BK</sc> nephropathy: The incidence and association with antibody-mediated rejection. Clinical Transplantation, 2018, 32, e13194.	0.8	35
13	Banff survey on antibody-mediated rejection clinical practices in kidney transplantation: Diagnostic misinterpretation has potential therapeutic implications. American Journal of Transplantation, 2019, 19, 123-131.	2.6	35
14	A method to reduce variability in scoring antibody-mediated rejection in renal allografts: implications for clinical trials - a retrospective study. Transplant International, 2019, 32, 173-183.	0.8	24
15	Ten Years of Kidney Paired Donation at Mayo Clinic: The Benefits of Incorporating ABO/HLA Compatible Pairs. Transplantation, 2020, 104, 1229-1238.	0.5	19
16	Factors at de novo donor-specific antibody initial detection associated with allograft loss: a multicenter study. Transplant International, 2019, 32, 502-515.	0.8	16
17	A 2020 Banff Antibody-mediated Injury Working Group examination of international practices for diagnosing antibody-mediated rejection in kidney transplantation - a cohort study. Transplant International, 2021, 34, 488-498.	0.8	15
18	Current Approaches to Desensitization in Solid Organ Transplantation. Frontiers in Immunology, 2021, 12, 686271.	2.2	14

#	ARTICLE	IF	CITATIONS
19	A study from The Mayo Clinic evaluated long-term outcomes of kidney transplantation in patients with immunoglobulin light chain amyloidosis. <i>Kidney International</i> , 2021, 99, 707-715.	2.6	13
20	Estimating alloantibody levels in highly sensitized renal allograft candidates: Using serial dilutions to demonstrate a treatment effect in clinical trials. <i>American Journal of Transplantation</i> , 2021, 21, 1278-1284.	2.6	12
21	The need for novel trial designs, master protocols, and research consortia in transplantation. <i>Clinical Transplantation</i> , 2020, 34, e13759.	0.8	11
22	Kidney Transplantation in Patients With Monoclonal Gammopathy of Renal Significance (MGRS)â€™Associated Lesions: A Case Series. <i>American Journal of Kidney Diseases</i> , 2022, 79, 202-216.	2.1	9
23	Death With Function and Graft Failure After Kidney Transplantation: Risk Factors at Baseline Suggest New Approaches to Management. <i>Transplantation Direct</i> , 2022, 8, e1273.	0.8	9
24	KDOQI US Commentary on the 2020 KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation. <i>American Journal of Kidney Diseases</i> , 2021, 77, 833-856.	2.1	7
25	Kidney Transplant Outcomes of Patients With Multiple Myeloma. <i>Kidney International Reports</i> , 2022, 7, 752-762.	0.4	7
26	Thinking Beyond New Clinical Guidelines: Update in Hypertension. <i>Mayo Clinic Proceedings</i> , 2015, 90, 273-279.	1.4	5
27	Hypertension in the Hemodialysis Patient. <i>Advances in Experimental Medicine and Biology</i> , 2016, 956, 327-340.	0.8	5
28	Is the level of HLA eplet mismatch a risk factor for graft loss among kidney transplant recipients who have already formed de novo donor specific antibody?. <i>Human Immunology</i> , 2021, 82, 240-246.	1.2	4
29	Long-term Immunosuppression Adherence After Kidney Transplant and Relationship to Allograft Histology. <i>Transplantation Direct</i> , 2018, 4, e392.	0.8	3
30	Measuring human leukocyte antigen alloantibodies: beyond a binary decision. <i>Current Opinion in Organ Transplantation</i> , 2020, 25, 529-535.	0.8	3
31	Modeling graft loss in patients with donor-specific antibody at baseline using the Birmingham-Mayo (BirMay) predictor: Implications for clinical trials. <i>American Journal of Transplantation</i> , 2019, 19, 2274-2283.	2.6	2
32	Unique Considerations When Managing Hypertension in the Transplant Patient. <i>Advances in Experimental Medicine and Biology</i> , 2016, 956, 341-353.	0.8	1
33	Apples, oranges, and anything in between: In search of the best desensitization therapy. <i>American Journal of Transplantation</i> , 2021, 21, 3825-3826.	2.6	1
34	Chronic Histologic Changes Are Present Regardless of HLA Mismatches. <i>Transplantation</i> , 2020, Publish Ahead of Print, e244-e256.	0.5	1
35	Maintaining the Health of the Renal Allograft. <i>Clinics in Laboratory Medicine</i> , 2018, 38, 607-621.	0.7	0
36	Imlifidase Shows Promise for the Most Disadvantaged Sensitized Transplant Candidates. <i>Transplantation</i> , 2021, 105, 1660-1661.	0.5	0

#	ARTICLE	IF	CITATIONS
37	Antibody-Mediated Rejection: the Role of Plasma Cells and Memory B Cells. Current Transplantation Reports, 2021, 8, 272-280.	0.9	0